Joseph Oliveto Sells 34,523 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 34,523 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $1.93, for a total transaction of $66,629.39. Following the sale, the chief executive officer directly owned 482,744 shares of the company’s stock, valued at approximately $931,695.92. This trade represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Joseph Oliveto also recently made the following trade(s):

• On Monday, December 15th, Joseph Oliveto sold 133,054 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.32, for a total transaction of $308,685.28.
• On Thursday, January 8th, Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.25, for a total transaction of $96,750.00.
• On Wednesday, January 7th, Joseph Oliveto sold 500 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total transaction of $1,125.00.

Milestone Pharmaceuticals Stock Down 2.6%

NASDAQ:MIST opened at $1.89 on Friday. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. Milestone Pharmaceuticals Inc. has a 12-month low of $0.63 and a 12-month high of $3.06. The stock’s fifty day simple moving average is $2.23 and its 200-day simple moving average is $1.96. The firm has a market capitalization of $160.97 million, a P/E ratio of -2.30 and a beta of 0.44.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. Equities research analysts expect that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Propel Bio Management LLC boosted its stake in Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after purchasing an additional 3,333,333 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter valued at about $6,444,000. Simplify Asset Management Inc. lifted its holdings in shares of Milestone Pharmaceuticals by 186.2% in the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after purchasing an additional 1,842,974 shares in the last quarter. Pathstone Holdings LLC bought a new position in shares of Milestone Pharmaceuticals during the third quarter worth about $2,000,000. Finally, Boxer Capital Management LLC bought a new position in shares of Milestone Pharmaceuticals during the third quarter worth about $1,333,000. 86.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on MIST shares. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Zacks Research raised Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Finally, Wells Fargo & Company increased their price target on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Key Stories Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone announced U.S. pharmacy availability of its CARDAMYST nasal spray — a commercial launch that begins the company’s transition from development to product revenue and increases commercial visibility. Read More.
• Positive Sentiment: Zacks Research upgraded MIST from “Hold” to “Strong Buy,” which can attract short‑term buyers and momentum flows into a thinly traded microcap. Read More.
• Neutral Sentiment: Technical/trading context is mixed: shares sit below the 50‑day moving average and current volume is below the stock’s average, which may limit a sustained rally despite the launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto executed large sales (133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93). Material insider reductions by the CEO often trigger investor concern about insider conviction and can add selling pressure. Read More.
• Negative Sentiment: Other senior insiders (COO Jeffrey Nelson, and executives David Bharucha and Lorenz Muller) also sold large blocks on Dec. 15 and Jan. 26, representing double‑digit percentage cuts to their stakes—a clustered pattern that intensifies negative sentiment and helps explain downward pressure on the share price. Read More. Read More. Read More.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.